多囊肾病饮食:已知与安全
本文综述常染色体显性多囊肾病(ADPKD)饮食干预(热量限制、间歇性禁食、生酮饮食)及补充剂的证据。临床证据有限,长期后果不确定;建议维持理想体重、高液体摄入、低钠、限制浓缩甜食。补充剂不推荐常规使用。
要点
- 热量限制可能对超重或肥胖ADPKD患者有益,促进体重下降并改善代谢参数。
- 间歇性禁食和生酮饮食在ADPKD中证据有限,长期安全性不确定。
- 姜黄素、银杏内酯B、皂苷、维生素E、烟酰胺、雷公藤内酯等补充剂临床获益不确定,不推荐使用。
核心结论
- 饮食干预如热量限制、间歇性禁食和生酮饮食通过改善代谢健康在ADPKD管理中显示前景,但需广泛临床研究确定有效性和长期影响。
- 遵循个体化饮食指南,包括体重管理和特定营养限制,有助于优化ADPKD管理。
研究设计与样本
- 综述:总结支持热量限制、间歇性禁食和生酮饮食在ADPKD中疗效与安全性的现有证据。
主要发现
- 临床前研究显示饮食干预有有利结果,但支持其有效性的临床证据有限。
- 饮食干预的长期后果,包括对ADPKD患者不良事件的影响,仍不确定。
- 热量限制似乎对超重或肥胖患者特别有益,因其促进体重下降并改善代谢参数。
- 补充姜黄素、银杏内酯B、皂苷、维生素E、烟酰胺或雷公藤内酯的临床获益不确定。
- β-羟基丁酸补充剂在动物模型中显示前景,但在ADPKD中的安全性和有效性需进一步评估。
关键数值与推荐
- 建议患者遵循旨在达到或维持理想体重的饮食方案,包括高液体摄入、低钠和限制浓缩甜食。
- 目前不推荐ADPKD患者使用姜黄素、银杏内酯B、皂苷、维生素E、烟酰胺或雷公藤内酯等补充剂。
- β-羟基丁酸补充剂的安全性和有效性需通过设计良好的临床试验进一步评估。
临床怎么用
- ADPKD患者应遵循个体化饮食指南,包括体重管理和特定营养限制。
- 超重或肥胖ADPKD患者可考虑热量限制以促进体重下降和改善代谢参数。
- 不推荐ADPKD患者常规使用姜黄素、银杏内酯B、皂苷、维生素E、烟酰胺或雷公藤内酯等补充剂。
局限性
- 支持饮食干预有效性的临床证据有限。
- 饮食干预的长期后果,包括对不良事件的影响,仍不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by kidney cyst formation and progressive kidney function loss. Dietary interventions such as caloric restriction, intermittent fasting, and ketogenic diet have recently emerged as potential strategies to induce metabolic reprogramming and slow ADPKD progression. We review the available evidence supporting the efficacy and safety of these interventions in ADPKD. Dietary interventions show promise in managing ADPKD by improving metabolic health and reducing oxidative stress. However, while preclinical studies have shown favorable outcomes, limited clinical evidence supports their effectiveness. In addition, the long-term consequences of these dietary interventions, including their effect on adverse events in patients with ADPKD, remain uncertain. To optimize ADPKD management, patients are advised to follow a dietary regimen that aims to achieve or maintain an ideal body weight and includes high fluid intake, low sodium, and limited concentrated sweets. Caloric restriction seems particularly beneficial for patients with overweight or obesity because it promotes weight loss and improves metabolic parameters. Supplementation with curcumin, ginkgolide B, saponins, vitamin E, niacinamide, or triptolide has demonstrated uncertain clinical benefit in patients with ADPKD. Notably, β -hydroxybutyrate supplements have shown promise in animal models; however, their safety and efficacy in ADPKD require further evaluation through well-designed clinical trials. Therefore, the use of these supplements is not currently recommended for patients with ADPKD. In summary, dietary interventions such as caloric restriction, intermittent fasting, and ketogenic diet hold promise in ADPKD management by enhancing metabolic health. However, extensive clinical research is necessary to establish their effectiveness and long-term effects. Adhering to personalized dietary guidelines, including weight management and specific nutritional restrictions, can contribute to optimal ADPKD management. Future research should prioritize well-designed clinical trials to determine the benefits and safety of dietary interventions and supplementation in ADPKD.
引用
- Chebib FT, Nowak KL, Chonchol MB, et al. Polycystic Kidney Disease Diet: What is Known and What is Safe. Clin J Am Soc Nephrol. 2023. PMID: 37729939. doi:10.2215/CJN.0000000000000326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。